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Abstract
Background—The pro-inflammatory cytokines, tumor necrosis factor (TNF)-α, and interleukin 
(IL)-17, have been implicated in the pathogenesis of liver fibrosis. In this study, we investigated 
the role of TNFα and IL-17 towards induction of profibrotic factor, periostin.
Methods—HepG2 cells were cultured and treated with inflammatory cytokines, TNFα and 
IL-17. Computational promoter sequence analysis of the periostin promoter was performed to 
define the putative binding sites for transcription factors. Transcription factors were analyzed by 
Western blot and Chromatin Immunoprecipitation. Periostin and transcription factor expression 
analysis was performed by RT-PCR, Western blot, and fluorescence microscopy. Type I collagen 
expression from fibroblast cultures was analyzed by Western blot and Sircol soluble collagen 
assay.
Results—Activation of HepG2 Cells with TNFα and IL-17 enhanced the expression of periostin 
(3.5 and 4.4 fold, respectively p<0.05) compared to untreated cells. However, combined treatment 
with both TNFα and IL-17 at similar concentration demonstrated a 13.3 fold increase in periostin 
(p<0.01), thus suggesting a synergistic role of these cytokines. Periostin promoter analysis and 
specific siRNA knock-down revealed that TNFα induces periostin through cJun, while IL-17 
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induced periostin via STAT-3 signaling mechanisms. Treatment of the supernatant from the 
cytokine activated HepG2 cells on fibroblast cultures induced enhanced expression of type I 
collagen (>9.1 fold, p<0.01), indicative of a direct fibrogenic effect of TNFα and IL-17.
Conclusion—TNFα and IL-17 induced fibrogenesis through cJun and STAT-3 mediated 
expression of profibrotic biomarker, periostin. Therefore, periostin might serve as a novel 
biomarker in early diagnosis of liver fibrosis.
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Introduction
Chronic liver disease is one of the top fifteen leading causes of death in the United States 
(Murphy et al., 2010). Most common causes of chronic liver disease include: viral hepatitis, 
alcoholism, metabolic and autoimmune diseases (Schuppan and Afdhal, 2008). The 
progression from healthy liver tissue to cirrhosis is mediated by a chronic inflammatory 
reaction eventually leading to the excess deposition of extracellular matrix proteins 
(Friedman, 2008). The inflammatory reaction is considered to be the key predictor of disease 
progression (Argo et al., 2009; Asselah et al., 2005). The accumulation of ECM proteins 
distorts the hepatic architecture by forming a fibrous scar, and the subsequent development 
of nodules of regenerating hepatocytes leading to cirrhosis. Hepatic fibrosis is generally 
considered to be an irreversible process manifested by a collapse in the hepatic parenchyma 
and its substitution with a collagen-rich tissue (Bataller and Brenner, 2005). Animal models 
and cell culture studies on liver fibrogenesis led to the identification of key fibrotic 
biomarkers (Hayashi and Sakai, 2011). Research and understanding in the pathogenesis of 
liver fibrosis could aid the development of novel therapeutic strategies to prevent and 
possibly reverse the disease progression.
Inflammation is an important starting event of liver fibrosis (Czaja, 2014). Inflammatory 
cytokine levels are elevated independently of the etiology of the underlying liver disease 
(Tilg et al., 2006). Among the pro-inflammatory cytokines, tumor necrosis factor-alpha 
(TNFα) is a potent cytokine that exerts pleiotropic inflammatory and immunological 
functions by triggering downstream signaling events leading to hepatic fibrosis (Osawa et 
al., 2013). Levels of circulating TNFα are increased in patients with liver fibrosis and are 
associated with poor prognosis (Odeh et al., 2005). Further in an experimental cholestasis 
induced by bile duct ligation TNFα and IL-6 were elevated indicating the pathogenic nature 
of these cytokines (Gabele et al., 2009; Odeh, 2007). Hepatic macrophages in chronic liver 
inflammation exhibit high levels of TNFα expression (Zimmermann et al., 2012). TNFα has 
also been demonstrated to induce fibrosis in other models. In a model of pulmonary fibrosis, 
TNFα receptor knockout mice were protected from the development of fibroproliferative 
lesions (MacEwan, 2002). Also, hepatic injury following administration of the hepatotoxin 
carbon tetrachloride was inhibited in TNFα knockout mice (Sudo et al., 2005). Along with 
TNFα alpha another inflammatory cytokine IL-17 has been implicated in the liver fibrosis 
(Tang et al., 2011). IL-17A plays a critical role in neutrophil recruitment, angiogenesis, 
inflammation, and autoimmune disease that has been previously described extensively 
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(Miyamoto et al., 2003), including in pulmonary and cardiac fibrosis via IL-17 receptor 
mediated signaling (Gasse et al., 2011; Zhu et al., 2011). Although these cytokines induce 
fibrotic events, to date, very limited data is available on fibrotic biomarkers with therapeutic 
value.
Periostin is a 90-kD secretory protein, playing an important role in the development of 
bones, teeth and tumor progression (Hamilton, 2008; Ruan et al., 2009). Recent evidence 
suggests that expression of periostin is involved in various pathophysiological statuses of 
fibrosis, including the healing process in myocardial infarction, pulmonary fibrosis and bone 
marrow fibrosis (Oka et al., 2007; Oku et al., 2008). Studies from lung models indicate that 
periostin contributes to the formation of fibrosis in response to inflammatory cytokines 
(Sidhu et al., 2010). In this report, we demonstrate that TNF and IL-17 exert a synergistic 
effect on HepG2 cells through two different signaling pathways leading to enhanced 
periostin expression and eventual induction of Type I collagen expression, a potential 
pathogenic mechanism in liver fibrosis.
Materials and Methods
Cell culture
HepG2 cells were obtained from the American Type Culture Collection (HB-8065, ATCC, 
Manassas, VA) and cultured in cell basal essential media (30–2003, ATCC, Manassas, VA) 
along with the media supplements as recommended by the manufacturers (Sarma et al., 
2014). Normal neonatal human fibroblasts (PCS-201-010™, ATCC, Manassas, VA) and 
normal adult human dermal fibroblasts (PCS-201-012, ATCC, Manassas, VA) were also 
obtained from the same vendor and cultured as per the manufacture’s protocol. Cell lines 
were frozen in liquid vapor nitrogen at −130°C until use. Upon thawing, cells were 
maintained in 5% CO2 incubator in sterile essential media at 37°C. Cells were then 
stimulated with varying concentration (0–1000 ng/mL) of TNF or IL-17 or both (Life 
Technologies, Grand Island, NY) for 48–72 hours. Specific siRNA (Santa Cruz Biotech, 
Dallas, TX) mediated gene knock-down of STAT-3 (sc-29493) and cJun (sc-29223). The 
knockdown efficiency was measured by qPCR. All experiments were performed in 
triplicates.
Total protein extraction and Western blot analysis
Total proteins were extracted from cells with lysis buffer (50mM HEPES [pH 7.6], 150mM 
NaCl, 1% Triton X-100, 30mM Na4P2O7, 10% glycerol, 1mM benzamidine, 1mM DTT, 
10µg of leupeptin/ml, 1mM phenylmethylsulfonyl fluoride 50mM NaF, 1mM sodium 
orthovandate, 10mM sodium pyrophosphate decahydrate, 10mM β-glycerophosphate 
(Sigma Aldrich, MO) (Tiriveedhi et al., 2012a). After cell lysis, the supernatant was 
collected and run at 15,000 × g for 15min at 4°C.
Nuclear Protein extraction
Nuclear proteins were extracted from HepG2 cells with initial resuspension in Buffer 1 with 
protease and phosphatase inhibitors (100mM HEPES, 5mM KCl, 0.5mM MgCl2, 0.1mM 
EDTA, 1mM DTT, 10µg/mL of aprotinin A, 10µg/mL of leupeptin, 1 mM PMSF, 50mM 
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NaF, 1mM sodium orthovandate, 10mM sodium pyrophosphate decahydrate, 10mM β-
glycerophosphate) and later resuspended in equivolume mix of Buffer 1 and Buffer 2 
(12.25mL of Buffer 1 + 250µL NP-40) to extract the cytosolic proteins from the supernatant. 
The resultant pellet of cell lysates were centrifuged at 12,000 × g for 1min at 4°C, and the 
remaining nuclear material were solubilized in Buffer 3 (250mM HEPES, 350mM NaCl, 
10% sucrose, 1mM EDTA, 1mM DTT, 10µg/mL of aprotinin A, 10µg mL of leupeptin, 
1mM PMSF) (Tiriveedhi et al., 2012a).
Protein concentration was determined with a Bradford assay kit from Bio-Rad 
(Philadelphia.PA). Total proteins were separated on a 4–12% sodium dodecyl sulfate-
polyacrylamide gradient gel and electrophoretically transferred onto a nitrocellulose 
membrane. The membranes were blocked overnight at 4°C in Tris-buffered saline with 
0.05% Tween 20 (5% nonfat milk in 10mM Tris-HCl-100mM NaCl-0. 1% Tween 20, pH 
7.4). The membranes were incubated first with Abs specific for total and phosphorylated 
forms at room temperature with primary Abs diluted 1 in 1,000 in blocking buffer for 2hrs, 
and then with a horseradish peroxide-conjugated secondary IgG mAb diluted 1 in 5,000 for 
1hr. All primary and secondary Abs were obtained from Santa Cruz Biotech (Dallas, TX). 
The following specific primary antibodies to periostin (sc-67233), STAT-3 (sc-482), c-Jun 
(sc-1694), and Actin (sc-10731) were utilized. Phosphorylated forms were probed with 
phospho-specific primary antibodies: Ser-727-p-STAT-3 (sc-21876) Thr-183/Tyr185/c-Jun 
(sc-293136), respectively. The membrane was developed using the chemiluminescence kit 
(Millipore) and analyzed on using Bio-Rad Universal Hood II (Hercules, CA). 
Morphometric analysis was done using the software provided by the company.
mRNA expression analysis
Expression profiles of intracellular signalling genes in the HepG2 cells were analyzed using 
the FAM-labeled RT-PCR primers for Periostin (Hs01566748_m1), c-Jun 
(Hs99999141_s1), Stat-3 (Hs01051722_s1), GADPH (Hs402869), Actin (Hs4333762T), 
and Type I collagen (Hs01103892_g1) obtained from Applied Biosystems/Life 
Technologies (Grand Island, NY) as per the manufacturer’s recommendation. Briefly, total 
RNA was extracted from 106 cells using TRIzol reagent (Sigma–Aldrich, St Louis, MO) 
(Tiriveedhi et al., 2012b). RNA samples were quantified by absorbance at 260nm. The RNA 
was reverse-transcribed and RT-PCR (real time PCR) was performed in a final reaction 
volume of 50µL using iCycler 480 Probes Master (Roche Diagnostics, Indianapolis, IN). 
Each sample was analyzed in triplicate. Cycling conditions consisted of an initial 
denaturation of 95°C for 15min, followed by 40 cycles of 95°C for 30s, followed by 61°C 
for 1min.
Immunofluorescence microscopy
For staining of periostin, 50,000 HEPG2 cells were grown on coverslips in 24-well plates 
(Sarma et al., 2014). Cells were fixed with 4% paraformaldehyde and permeabilized with 
0.1% Triton X-100. 2% normal goat serum in DPBS (Dulbecco’s phosphate-buffered saline, 
Life Technologies, Grand Island, NY) with 1% BSA, 0.1% Tween 20 was used for blocking 
and washing. The specific primary antibodies and corresponding PE-conjugated 
immunofluorescence antibodies (eBioscience, SanDiego, CA) were used. The images were 
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captured using an Eclipse 80i fluorescence microscope (Nikon, NY) and processed using 
Metamorph version 6.3r2 software (Molecular Devices, CA).
Plasmids and siRNA constructs
For the reporter constructs, the periostin promoter regions (−4000 to +50 bp) were amplified 
from human genomic DNA (Zyagen, CA) by PCR using iProof High-Fidelity DNA 
Polymerase (Bio-Rad, CA). The PCR products were subcloned into the pGL4.11 vector 
(Promega, WI) upstream of a luciferase gene using the KpnI/EcoRV restriction sites. 
Computational analysis to identify promoter-bound transcription factors was done using the 
Transcription Element Search System (TESS) (http://www.cbil.upenn.edu/cgi-bin/tess/tess).
Luciferase reporter assay
HepG2 cells (1 × 105) were transfected in 24-well plates with 1 µg pGL4.11 luciferase 
reporter vector driven by the periostin promoters, or with 2 µg control vector (Sarma et al., 
2014). For transfection of HEPG2 cells (ATCC), 0.2×105 cells were seeded into each well 
of a 24 well plate and grown for 24–48 hours. On the day of transfection, medium was 
changed and 500 ng of DNA was transfected using Lipofectamine™ LTX and Plus Reagent 
(Invitrogen, NY). For siRNA delivery 0.1×105 cells were grown in each well of a 24 well 
plate for 24–48 hours in antibiotic free medium and 80 pico moles of siRNA were 
transfected using Lipofectamine™ RNAiMAX (Invitrogen, NY). Cells were harvested 48 
hours post transfection and efficiency was measured by qPCR, immunostaining and western 
blot.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was carried out with ChIP-IT Express (Active 
Motif, CA) according to the manufacturer's instructions (Sarma et al., 2014). One 
microgram of Abs for control IgG, c-Jun, or STAT3, was used to immunoprecipitate DNA-
protein complexes. CCL2 promoter regions were amplified using PCR and resolved on 2% 
agarose gels. The images were acquired with the Chemidoc XRS System (Bio-Rad).
Co-immunoprecipitation
For cJun and STAT-3 immunoprecipitation HepG2 cells were washed with cold DPBS, and 
lysed for 30 min on ice with 0.5 mL of lysis buffer (10 mM Tris-HCl pH 7.5, 0.4 M NaCl, 
1% NP-40, 0.4% Triton X-100, 0.2% sodium deoxycholate, 1 mM EDTA, protease 
inhibitors (Roche), 1 mM PMSF). To the lysis buffer 0.5 mL of dilution buffer (10 mM Tris-
HCl pH 7.5, 1 mM EDTA, protease inhibitors, 1 mM PMSF) was added, followed by 
centrifugation at 17,000 × g for 30 min. The supernatant was transferred and 1 µg normal 
mouse IgG or mouse anti-cJun or mouse anti-STAT-3 were added. After overnight 
incubation at 4°C, 30 µL Protein G beads were added to lysates and incubated for 2 hours. 
Beads were washed with 700 µL of wash buffer (10 mM Tris-HCl pH 7.5, 0.2 M NaCl, 
0.5% NP-40, 0.2% Triton X-100, 0.1% sodium deoxycholate, 1 mM EDTA, 1× protease 
inhibitors, 1 mM PMSF) five times, 3 min each time followed by centrifugation at 1,800 × g 
for 3 min at 4°C. Beads were then washed with cold DPBS and bound proteins were eluted 
by boiling with 30 µL of 2× SDS buffer (0.1 M Tris-HCl pH 6.8, 3.5% SDS, 10% Glycerol, 
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2 mM DTT, 0.004% bromophenol blue) for 10 min. Proteins were subjected to SDS-PAGE 
(4–12% gel) and immunoblotting. cJun or STAT-3 were detected with a rabbit anti-cJun or a 
rabbit anti-STAT-3 respectively.
Enzyme-linked immunoassay (ELISA)
The secretory extracellular periostin in the cell supernatant was quantitatied by ELISA. 
Periostin ELISA was performed as per the manufacturer’s protocol (BioVision Inc, Milpitas, 
CA). Given the limitation of the detection, the supernatant was diluted 1:1000 and quantified 
with a standard curve using the manufacturer provided standards. Detection at 450 nm was 
performed using EMax Plus spectrophotometer and data analysis was carried out using 
software provided by the manufacturer (Molecular Devices, Sunyvale, CA).
Collagen Assay
Total soluble collagen content in cell lysates was measured using Sircol soluble collagen 
assays (CRLS1000) as described in the manufacturer’s protocol (Accurate Chemical ad 
Scientific Corp, Westbury, NY) (Sidhu et al., 2010). Cells were prepared by washing with 
cold PBS solution, treated with 0.5 M acetic acid, freeze/thawed, and digested with pepsin 
overnight at 4 °C. Samples were centrifuged to remove insoluble debris then incubated with 
Sircol dye reagent for 30 min at room temperature on a shaker. Samples then spun to pack 
the insoluble collagen–dye complex and excess liquid decanted off. One milliliter of alkali 
reagent was then added and mixed to dissolve bound dye and samples were assayed at 540 
nm on a EMax Plus spectrophotometer and data analysis was carried out using software 
provided by the manufacturer (Molecular Devices, Sunyvale, CA). Collagen standards were 
used as controls.
Statistical analysis
Data are expressed as mean ± SEM from four independent studies. Statistical differences 
between means were analyzed using a paired or unpaired Student’s t test. A p-value of less 
than 0.05 was considered significant. All data analysis was obtained using Origin 7 software 
(Origin Labs, Northampton, MA) or GraphPad5 (Graph Pad Software, LaJolla, CA).
RESULTS
Increased expression of periostin upon activation of Hep-G2 cells with TNFα and IL-17
Studies in the literature have reported the role of TNFα and IL-17 in hepatic fibrosis. As 
periostin is a key pro-fibrotic signal molecule and biomarker, we performed experiments to 
determine the role of these pro-inflammatory cytokines in the expression of the periostin 
protein. We have treated the HepG2 cells, a perpetual hepato carcinoma cell line, with 50 
ng/mL of either TNFα, or IL-17, or a combination of both cytokines. As shown in figure 
1A, intracellular immunohistochemical staining of HepG2 cells for periostin demonstrated 
an increased expression of the protein following co-treatment with both TNFα and IL-17. 
This is further verified by western blot analysis (figure 1B). Quantitative mRNA analysis of 
the periostin (figure 1C) demonstrated that under basal conditions there was minimal to no 
expression of periostin (1.0 ± 0.2 fold), but following treatment with either TNFα or IL-17 
alone there was a significant elevation of periostin mRNA expression (3.5 ± 1.1 fold and 4.4 
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± 0.9 fold, respectively p<0.05). However, a co-treatment of both TNFα and IL-17 
demonstrated a 13.3±3.8 fold increased expression (p<0.05) over the basal conditions. 
Importantly, treatment with anti-inflammatory cytokine IL-10 demonstrated no enhanced 
expression of periostin (0.5 ± 0.3 fold, p=0.83) over basal conditions. Further dose-
dependent studies were performed using various concentrations (1 to 1000 ng/mL) of TNFα 
and Il-17. As shown in figure 1D and E, individual treatment with these pro-inflammatory 
cytokines only induced a maximum of 3.5 fold enhanced expression even at 1000 ng/mL 
concentration, as against 13.3 fold expression with co-treatment (50 ng/mL of TNFα+50 
ng/mL of IL-17). Thus we demonstrate that co-treatment with TNFα and IL-17 caused 
approximately a 4 fold increase above the individual cytokine treatment with either TNFα or 
IL-17. It is important to note in dose response curves (figure 1D ad E) that individual 
treatment with 50 ng/mL TNFα or IL-17 lead to almost (>90%) saturation kinetics for that 
specific cytokine. These data indicate that TNFα and IL-17 exert a synergistic effect. 
Furthermore, as the synergistic effect was shown to be higher than the individual saturation 
effect, this strongly suggests a possibility of two different pro-fibrotic signaling mechanisms 
induced by these two cytokines.
Specific Modulation of periostin expression by cJun and STAT3
Based on our previous studies (figure 1) we performed experiments to determine the 
transcription factors to specifically delineate the pro-fibrotic signaling events mediated by 
TNFα and IL-17. Towards this, we have initially analyzed various transcription factors by 
quantitative RT-PCR and found that cJun and STAT-3 demonstrated significantly enhanced 
expression. The other transcription factors which we tested and did not induce a significant 
change under our current experimental conditions were AP-1, p38, STAT-1, STAT-2, 
STAT-5, Akt, mTOR. Western blot (and phosphoblot) studies (figure 2A) following 
treatment with 50 ng/mL of TNFα on Hep G2 cells for 30 minutes demonstrated is an 
enhanced expression and phosphorylation of cJun while similar dose and conditions with 
IL-17 induced an enhanced expression and phosphorylation of STAT-3. However, co-
treatment with TNF and IL-17 demonstrated expression and phosphorylation of both cJun 
and STAT-3. Quantitative analysis by qRT-PCR demonstrated that there was a 4.4 fold 
upregulation of total cJun (figure 2B) following treatment with TNFα, which did not 
increase further upon co-treatment with both TNFα and IL-17. Similarly, there was a 3.7 
fold upregulation in total STAT-3 (figure 2C) following treatment with IL-17, which did not 
increase further change upon co-treatment with both TNFα and IL-17. These data support 
our previous assertion that TNFα and IL-17 potentially induce periostin expression through 
two different signaling factors.
To confirm that TNFα and IL-17 induce separate pro-fibrotic signaling we performed 
siRNA knockdown experiments specific for cJun and STAT-3. As shown in figure 2D, 
siRNA knockdown of cJun and STAT-3, individually, following co-treatment with TNFα 
and IL-17 demonstrated reduced intracellular staining for periostin. As expected, combined 
knock-down of both cJun and STAT-3 completely abolished the periostin expression. This is 
further verified by western blot analysis (figure 2E). Quantitative mRNA analysis of the 
periostin (figure 2F) demonstrated that cJun knock-down reduced the periostin expression to 
5.1± 1.8 fold, while STAT-3 knock-down reduced the periostin expression to 4.6± 1.5 fold 
Amara et al. Page 7






















in previously TNFα and IL-17 co-treated HepG2 cells. As noted earlier in figure 2F, TNFα 
and IL-17 co-treatment induced periostin expression (13.3±2.8 fold over basal untreated 
levels). Taken together these data confirm that TNFα and IL-17 induce pro-fibrotic 
signaling molecule, periostin, in two apparently different signaling mechanisms.
Identification of putative DNA binding transcription factors in the periostin promoter 
regions
To determine the role of TNFα and IL-17 in periostin expression, the luciferase reporter 
construct (figure 3A) containing the −4,000-bp region of the human periostin gene promoter 
was transfected into HepG2 cells and treated with TNFα or IL-17 or both, and luciferase 
activity was measured. An increase in the periostin reporter activity was observed in TNFα 
(6.5 fold, figure 3B) and IL-17 (7.8 fold, figure 3C) treated cells compared to the untreated 
cells. Further co-treatment with both TNF and IL-17 demonstrated a 26.3 fold increase 
(figure 3D) in Luciferase activity compared to the untreated cells. These data were in line 
with our earlier data (figure 1–3) supporting our contention that TNF and IL-17 work 
synergistically to ehance periostin expression. Also, this strongly suggests that TNF and 
IL-17 activates periostin through modulation of upstream transcription factors cJun and 
STAT-3.
To further specifically identify the putative DNA binding sequences for the transcription 
factors in the periostin promoter regions, a computational analysis of −4,000 bp of the 
promoter region was performed using TESS. This bioinformatics analysis identified 12 
putative DNA binding sites for for c-Jun (TGAGTCA; TGAC/GTCA), and one site for 
STAT3 (TTCTTTTGAA) at the bp −2657 position (figure 3A) with putative cJun and 
STAT-3 binding sequences close proximity to each other, suggesting that these two 
transcription factors may be part of a transcriptional-regulatory complex that mediates 
periostin expression. To demonstrate that these transcription factors regulate periostin 
expression, HepG2 cells were transfected with the truncated periostin reporter construct and 
treated with TNFα, or IL-17 or both (figure 3B–D). As shown in figure 3B, following 
treatment with TNFα various truncated regions showed significant decrease (>40% loss of 
activity) in reporter activity compared to the non-truncated periostin reporter activity. Of 
note, the mutation at −3857 (*TGAGTCA) resulted in highest (>80%) loss of activity. Thus 
strongly suggesting that this putative sequence region interacts with the cJun following 
TNFα treatment to enhance periostin expression. Similarly, following treatment with IL-17 
among various truncated regions the mutation at −2657 (*TTCTTTTGAA) resulted in 
highest (>80%) loss of activity compared to the non-truncated periostin reporter activity. As 
expected, these two mutants demonstrated highest loss of activity following co-treatment 
with TNFα and IL-17 (figure 3D), this strongly suggesting a cooperation between the 
factors in regulating periostin expression.
To determine whether cJun and STAT3 bind to adjacent DNA binding sites on the periostin 
promoter to form a transcriptional-activation DNA-protein complexes, TNFα, IL-17 or both, 
treated HepG2 cells were immunoprecipitated with anti-cJun, or anti-STAT3, or control 
IgGs. The chromatin immunoprecipitation (ChIP) and PCR using primers specific for 
periostin promoter regions (figure 3E, black bars) demonstrated that cJun, and STAT3 bind 
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to the periostin promoter (figure 3E). cJun binds strongly to the −4000 to −3000 bp region 
and STAT-3 binds to −3000 to −2000 bp region of the PCR amplicon. The DNA binding 
pattern of cJun and STAT-3 strongly correlates with the locations of the consensus binding 
sites on the periostin promoter determined by Luciferase reporter activity (figure 3B–D). 
ChIP with the control IgGs did not enrich periostin promoter regions, demonstrating the 
specificity for these transcription factors. No binding was observed in PCRs carried out with 
primers specific for the 300 to+50 bp region of the ACTIN (ACT1) promoter that lacks these 
binding sites (figure 3E). The protein-protein complexes were immunoprecipitated with anti-
cJun or anti-STAT-3 or isotype control IgGs and western blot analysis was performed to 
probe for the other protein (figure 3F, upper panel: probe with c-Jun antibody and protein 
complex pulled down with Stat-3 antibody; lower panel probe with Stat-3 antibody and 
protein complex pulled down with c-Jun antibody) supported our contention from the 
chromatin immunoprecipitation findings that cJun and STAT-3 were complexed together on 
the periostin promoter. Taken together, these data clearly demonstrate that the transcription 
factors cJun and STAT-3 synergistically interact and are part of a larger transcription-
regulatory complex enhancing the periostin gene expression.
Type I Collagen-I expression following activation of fibroblasts with periostin supernatant
Both TNFα and IL-17 have been implicated in collagen deposition in liver fibrosis. Periostin 
being a secretory protein should be secreted into the supernatant by the HepG2 cells 
following cytokine stimulation. We therefore determined the direct periostin mediated 
fibrotic effect of TNF and IL-17 by treating the fibroblasts with supernatants taken from the 
HepG2 cells treated with TNFα, or IL-17, or both. The HepG2 cells were first stimulated by 
either TNFα, or IL-17, or both for 48 hours, following which the cells were washed and the 
fresh media with not stimulating cytokines was added. The supernatant from this replaced 
media was obtained after 24 hours and utilized for periostin quantization and fibroblast 
stimulation. As shown figure 4A, following treatment of HepG2 cells with TNFα and IL-17 
there was increased in the secretion of the periostin into the supernatant (4.3 ± 0.52 µg/mL), 
as compared with individual TNFα (1.2 ± 0.26 µg/mL) or IL-17 (1.3 ± 0.31 µg/mL) 
stimulation. Normal neonatal human fibroblasts (figure 4B) and normal adult human dermal 
fibroblasts (figure 4C) were treated with supernatant for untreated HepG2 cells showed 
basal level of type I collagen expression (1.0±0.3 fold). The normal neonatal human 
fibroblasts (figure 4D) treated with supernatant from HepG2 cells treated with TNFα 
(2.4±0.5 fold, p<0.05) and IL-17 (3.3±0.4 fold, p<0.05) increase in collagen type I 
expression. As expected, the fibroblasts treated with supernatant from HepG2 cells co-
treated with TNFα and IL-17 (9.1±1.8 fold, p<0.01) increase in collagen type I expression. 
Sircol color assay for the soluble collagen expression from normal neonatal human 
fibroblasts (figure 4E) demonstrated that treatment of these cells with supernatant from 
HepG2 cells induced basal levels of collagen expression (2.7±0.6 µg/mL) while supernatant 
from HepG2 cells treated with TNFα (5.2±0.9 µg/mL, p<0.05), IL-17 (5.9±1.1 µg/mL, 
p<0.05), and TNFα and IL-17 (10.1±2.3 µg/mL, p<0.01) induced enhanced collagen 
expression. Similarly normal human adult dermal fibroblasts (figure 4F) treated with 
supernatant from HepG2 cells treated with TNFα (1.7±0.4 fold, p<0.05) and IL-17 (2.1±0.5 
fold, p<0.05) increase in collagen type I expression. As expected, the normal human adult 
dermal fibroblasts treated with supernatant from HepG2 cells co-treated with TNFα and 
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IL-17 (6.1±1.1 fold, p<0.01) increase in collagen type I expression. Sircol color assay for 
the soluble collagen expression from normal human adult dermal fibroblasts (figure 4G) 
demonstrated that treatment of these cells with supernatant from HepG2 cells induced basal 
levels of collagen expression (0.6±0.2 µg/mL) while supernatant from HepG2 cells treated 
with TNFα (2.8±0.6 µg/mL, p<0.05), IL-17 (3.9±0.7 µg/mL, p<0.05), and TNFα and IL-17 
(7.8±1.9 µg/mL, p<0.01) induced enhanced collagen expression. These findings from two 
different fibroblast cell lines confirm that TNFα and IL-17 induce periostin mediated 
fibrosis which might potentially explain for the inflammatory cytokine mediated liver 
fibrosis in cirrhotic patients.
Discussion
Liver fibrosis and cirrhosis represent the final common pathway of all chronic liver diseases 
(Xu et al., 2012). It results in liver failure and portal hypertension and is associated with an 
increased risk of liver cancer (Gines et al., 2004). Advanced hepatic fibrosis is characterized 
by an accumulation of type I and III collagens (Iredale, 2007). Further, models of liver 
fibrosis, which include cell culture, animal and explanted human tissue, have demonstrated 
that live fibrosis is a highly dynamic example of solid organ wound healing (Bataller and 
Brenner, 2005). Currently the only effective available treatment for cirrhosis is liver 
transplantation (Murray and Carithers, 2005). However, shortages of organs and the 
presence of concurrent diseases in the donors limit the availability of this treatment to all 
patients (Murray and Carithers, 2005). Clearly, development of novel anti-fibrotic therapies 
are needed to improve the morbidity and mortality of these patients (Cohen-Naftaly and 
Friedman, 2011). Increased understanding of the pathogenesis of liver fibrosis in past two 
decades lead to the identification of the main cellular effectors of liver fibrosis, the key 
cytokines regulating the fibrotic process, and the determinants of ECM turnover, 
highlighting an array of potential therapeutic approaches that could be developed in the near 
future (Cohen-Naftaly and Friedman, 2011).
Evidence on the role of periostin in liver diseases is limited. To date, the majority of reports 
on periostin in liver have ben predominantly from liver tumors and bile duct carcinomas 
(Riener et al., 2010). However, periostin has been extensively studied in various 
inflammatory lung diseases. Takayama et al (Takayama et al., 2006) using a murine model 
for bronchial asthma have demonstrated that periostin plays a key role in alveolar sup-
epithelial fibrosis under stimulation of pro-inflammatory cytokines IL-4 and IL-13. Later 
studies by Fahy and colleagues (Woodruff et al., 2007; Woodruff et al., 2009) have 
confirmed the upregulation of periostin in asthma patients. The pathological role of periostin 
and the precise molecular mechanisms leading to inflammation induced upregulation of 
periostin still remain unknown. In line with these published data, our current studies 
demonstrate that pro-inflammatory cytokines TNFα and IL-17 work synergistically towards 
enhanced expression of periostin (figure 1) in HepG2 cells, thus suggesting a potential role 
of periostin in liver inflammatory injury. Furthermore, it of interest to note that, not just 
limited to liver, the synergistic effect of TNFα and IL-17 have also been noted in other 
inflammatory diseases such as psoriasis leading to altered keratinocyte differentiation 
(Chiricozzi et al., 2011).
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Inflammatory cytokines, TNFα and IL-17, have been implicated in several fibrotic and liver 
diseases (Osawa et al., 2013; Tang et al., 2011). Therefore, in our current report we studied 
the molecular events leading to the upregulation of periostin in liver cells following 
stimulation with pro-inflammatory cytokines TNF and IL-17. Murine TNFα receptor knock 
out models have demonstrated that TNFα stimulated collagen synthesis, increased 
expression of TIMP-1, and decreased activity of MMP-2 (Theiss et al., 2005; Verrecchia et 
al., 2002). Similar to TNFα, Meng et al. (Meng et al., 2012), using a murine liver fibrosis 
model have demonstrated that hepatic stellate cells activation by IL-17 induces collagen 
deposition and fibrosis using a STAT-3 signaling mechanism. In our current studies we 
demonstrated that TNFα and IL-17 exert synergistic effect towards enhanced expression of 
periostin. TNFα induced expression of periostin through the transcription factor c-Jun, while 
IL-17 induced expression through STAT-3 (figure 3). Both these transcription factors act on 
the periostin promoter forming a transcription regulator complex, and there by inducing 
periostin expression (Figure 4). We have previously demonstrated that STAT-3 plays a 
criticial role in IL-6 induced CCL2 expression in hepatitis patients developing cirrhosis and 
acute liver failure (Sarma et al., 2014). In line with our current studies, Kluwe et al (Kluwe 
et al., 2010) have previously demonstrated that in carbon tetrachloride induced murine liver 
fibrosis model, inhibition of c-Jun inhibits the development and progression of hepatic 
fibrosis. Further, it is of interest to note that patients with chronic hepatitis C who displayed 
decreased fibrosis in response to the angiotensin receptor type 1 blocker losartan showed 
decreased cJun expression and phosphorylation (Kluwe et al., 2010). The role of IL-17 
mediated collagen deposition in a matrix metaloproteinase (MMP) mediated manner was 
also established in other chronic inflammatory diseases such as rheumatoid arthritis (Koshy 
et al., 2002). The c-Jun/JNK pathway is known to induce fibrosis in kidney (Ma et al., 2007) 
and lung diseases (Tiriveedhi et al., 2012a). Previous studies in our lung transplant models 
demonstrated that cJun activation by hypoxia inducble factor (HIF1α) potentially induced 
VEGF upegulation with potential fibrotic effect (Tiriveedhi et al., 2012a). Prele et al have 
demonstrated that STAT-3 is the key central factor in inducing idiopathic pulmonary 
disease, a fibrotic lung disease (Prele et al., 2012). Transcription factor STAT-3 is involved 
in JAK/STAT signaling pathway. Mice with STAT-3-deficient hepatocytes exhibit defects 
in their ability to induce acute phase response genes such as, serum amyloid protein, 
fibrinogen, haptoglobin, serum amyloid A protein, and hemopexin in response to 
inflammatory cytokine activation (Alonzi et al., 2001). This body of evidence along with our 
current studies strongly suggest the potential application of periostin, c-Jun, and STAT-3 as 
potential fibrotic biomarkers with potential anti-fibrotic drug target application. Our current 
study was limited with the high concentration of cytokines needed for cell culture studies. 
Therefore further studies in animal models and human diseases studies are warranted.
Conclusion
Currently, liver biopsy is the only clinical diagnostic method for diagnosis of liver fibrosis 
(Bataller and Brenner, 2005). Although this technique has the advantage of staging the liver 
fibrosis, characterizing the parenchymal architecture, a number of inherent problems also 
limit the accuracy of liver biopsy in determining fibrosis stage (Adams, 2011). It has been 
estimated a standard liver biopsy represents 1/50 000th of the liver, and thus sampling error 
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is a significant problem (Adams, 2011). The mere invasive nature of this procedure, limits 
the use only on patients with high degree of suspicion. A development of less-invasive 
fibrotic biomarker detection strategy would be a futuristic diagnostic strategy. Using indirect 
liver enzyme markers such as aminotransferases would not be a good marker for fibrotic 
activity (Rosenberg et al., 2004). Currently, inflammatory cytokine levels (TNFα, TGFβ etc) 
are the employed as anecdotal markers of fibrotic activity (Rosenberg et al., 2004). Periostin 
being a secretory protein could be a potential biomarker for liver fibrosis. Further clinical 
research to ascertain the sensitivity and specificity of periostin as a novel fibrotic biomarker 
could be immensely beneficial in the early diagnosis of patients potentially developing liver 
fibrosis.
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• TNFα, and IL-17 have been implicated in the pathogenesis of liver fibrosis.
• TNFα through induction of cJun and IL-17 through induction of STAT-3 exert a 
synergistic effect on the expression of periostin.
• Periostin induces collagen deposition.
• Therefore, periostin could be used a novel biomarker for early liver fibrosis.
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Increased periostin expression in HepG2 cells following stimulation with TNFα and IL-17. 
(A) Immunostaining of HepG2 cells with periostin following treatment with with TNFα (50 
ng/mL), or IL-17 (50 ng/mL) or both (TNFα-50 ng/mL and IL-17–50 ng/mL). Periostin 
probed with rabbit anti-human primary antibody at 1: 100 and later probed by PE-
conjugated oat anti-rabbit secondary antibody at 1:200. (B) Western blot analysis of 
perisotin expression in the hepG2 cells. The cell lystate probed by appropriate primary and 
secondary antibody. The representative periostin protein band at 93 kDa is shown. Anti-
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inflammatory cytokine IL-10 was utilized as negative control at two concentrations 50 and 
100 (2×) ng/mL. (C) Periostin mRNA expression analyzed by quantitative RT-PCR. 
Quantitation done by ΔΔcT method normalized for GADPH expression. (D and E) Dose 
dependent changes in the mRNA expression of periostin in the HepG2 cells following 
stimulation by TNFα (0–1000 ng/mL) (D) and IL-17 TNFα (0–1000 ng/mL) (E). All data 
represented as mean values ± SEM from four independent experiments.
Amara et al. Page 18























Induction of transcription factors cJun and STAT-3 in HepG2 cells following stimulation 
with TNFα and IL-17, respectively. (A) Western blot analysis was performed to determine 
the protein level expression of cJun (43 kDa), p-cJun (43 kDa), STAT-3 (86 kDa), p-
STAT-3 (86 kDa), STAT-6 (116 kDa), and Actin (43 kDa) for both total and active 
phosphorylated forms analyzed after 30 min stimulation with TNFα, or IL-17 or both; (B 
and C) quantitative mRNA expression of cJun (B), and STAT-3 (C) by qRT-PCR analyzed 
after 30 min stimulation with TNFα, or IL-17 or both. Quantitation done by ΔΔcT method 
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normalized for GADPH expression. (D) Immunostaining of HepG2 cells with periostin 
following treatment with with both TNFα and IL-17, and specific siRNA knock down of 
cJun and STAT-3. (E) Western blot analysis of perisotin expression in the hepG2 cells 
following stimulation with TNFα and IL-17 along with cJun and STAT-3 knock-down by 
specific siRNA. Scramble siRNA usd as negative control. (F) Periostin mRNA expression 
analyzed by quantitative RT-PCR in the hepG2 cells following stimulation with TNFα and 
IL-17 along with cJun and STAT-3 knock-down by specific siRNA. Quantitation done by 
ΔΔcT method normalized for GADPH expression. All data represented as mean values ± 
SEM from four independent experiments.
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cJun and STAT-3 bind to periostin promoter and activate transcription. (A) Schematic of the 
periostin gene promoter cloned in the luciferase reporter. Computational analysis of −4000 
bp upstream of the open reading frame using the Transcription Element Search System 
(TESS). The lines in the schematic at −3857 and −2657 represent the predicted consensus 
binding sites in the DNA for transcription factors cJun and STAT-3, respectively. (B–D) 
HepG2 were transfected with luciferase reporters driven by deletion constructs of periostin 
promoter (−4000 to+50 bp; −4000 to −1000 bp; −4000 to −2000 bp; −4000 to −3000 bp; 
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−2000 to +50 bp; mutation *Δ2657 bp/−4000 to +50 bp; and mutation *Δ3857 bp/−4000 to 
+50 bp) construct and stimulated with TNFα (B), or, IL-17 (C), or both (D). Firefly 
luciferase activity was measured 48 hours after transfection and normalized to a Renilla 
luciferase internal control. The numbers represent fold-change over the control vector 
(average of three independent experiments); error bars represent S.D. (E) Periostin promoter 
showing binding sites for cJun and STAT-3. The black horizontal bars represent regions 
amplified by the PCR primers. Chromatin was immunoprecipitated with anti-cJun or anti-
STAT-3 or isotype control IgG from HepG2 cells following stimulation with both TNFα 
and IL-17. Segments of the periostin promoter were amplified by PCR. The first three lanes 
show immunoprecipitated with chromatin (ChIP) and the fourth lane show input chromatin 
(Input). ACTIN promoter amplification is shown as the negative control (F) Co-
Immunoprecitation of protein-complex extracted by anti-STAT-3 and anti-cJun and Western 
blot analysis to probe with the opposite antibody (upper panel: probe with c-Jun antibody 
and protein complex pulled down with Stat-3 antibody; lower panel probe with Stat-3 
antibody and protein complex pulled down with c-Jun antibody).
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Induction of Collagen expression following activation of fibroblasts with periostin rich 
supernatant. (A) Quantitative ELISA analysis of the periostin secreted into the supernatant 
by HepG2 cells following stimulation with TNFα, or IL-17, or both. (B) Western blot 
analysis of the Type-I Collagen expressed by the normal neonatal human fibroblasts 
following treatment with supernatant from HepG2 cells stimulated with TNFα, or IL-17 or 
both. (C) Western blot analysis of the Type-I Collagen expressed by the normal adult human 
dermal fibroblasts following treatment with supernatant from HepG2 cells stimulated with 
TNFα, or IL-17 or both. (D) Densitometric analysis to determine quantitative expression of 
Collagen-I in normal neonatal human fibroblasts (under various conditions mentioned in B). 
(E) Sircol assay to demonstrate the expression of soluble collagen by fibroblasts in normal 
neonatal human fibroblasts (under various conditions mentioned in B). (F) Densitometric 
analysis to determine quantitative expression of Collagen-I in normal adult human dermal 
fibroblasts (under various conditions mentioned in C). (G) Sircol assay to demonstrate the 
expression of soluble collagen by fibroblasts in normal adult human dermal fibroblasts 
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(under various conditions mentioned in C). All data represented as mean values ± SEM from 
four independent experiments.
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